MIM
PPH icon

Macroview Investment Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Macroview Investment Management’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-144
Closed -$13.7K – 418
2024
Q3 		$13.7K Sell
144
-3
-2% -$285 0.01% 205
2024
Q2 		$13.4K Buy
147
+83
+130% +$7.41K 0.01% 206
2024
Q1 		$5.8K Hold
64
– – 0.01% 382
2023
Q4 		$5.21K Buy
64
+1
+2% +$78 0.01% 397
2023
Q3 		$5.03K Hold
63
– – 0.01% 425
2023
Q2 		$4.96K Hold
63
– – 0.01% 346
2023
Q1 		$4.89K Hold
63
– – 0.01% 320
2022
Q4 		$4.9K Hold
63
– – 0.01% 320
2022
Q3 		$4K Buy
63
+24
+62% +$1.77K 0.01% 307
2022
Q2 		$3K Buy
+39
New +$3.04K ﹤0.01% 353
2021
Q1 		– Sell
-300
Closed -$20K – 402
2020
Q4 		$20K Hold
300
– – 0.03% 117
2020
Q3 		$19K Hold
300
– – 0.03% 116
2020
Q2 		$19K Hold
300
– – 0.04% 105
2020
Q1 		$16K Hold
300
– – 0.03% 107
2019
Q4 		$19K Hold
300
– – 0.04% 118
2019
Q3 		$17K Hold
300
– – 0.04% 120
2019
Q2 		$18K Hold
300
– – 0.05% 123
2019
Q1 		$18K Sell
300
-463
-61% -$27.4K 0.04% 128
2018
Q4 		$42K Hold
763
– – 0.13% 74
2018
Q3 		$49K Buy
763
+1
+0.1% +$62 0.15% 68
2018
Q2 		$45K Buy
762
+1
+0.1% +$58 0.16% 65
2018
Q1 		$43K Buy
761
+1
+0.1% +$60 0.15% 62
2017
Q4 		$45K Buy
760
+1
+0.1% +$57 0.21% 43
2017
Q3 		$44K Buy
759
+1
+0.1% +$57 0.22% 42
2017
Q2 		$45K Sell
758
-398
-34% -$22.5K 0.24% 39
2017
Q1 		$64K Sell
1,156
-3,302
-74% -$179K 0.37% 27
2016
Q4 		$234K Sell
4,458
-1,034
-19% -$55.2K 1.28% 18
2016
Q3 		$316K Sell
5,492
-1,778
-24% -$107K 1.41% 18
2016
Q2 		$426K Buy
+7,270
New +$424K 1.89% 16
2016
Q1 		– Sell
-23,748
Closed -$1.55M – 110
2015
Q4 		$1.55M Sell
23,748
-43,900
-65% -$2.84M 4.96% 6
2015
Q3 		$4.26M Sell
67,648
-24,516
-27% -$1.72M 7.78% 4
2015
Q2 		$6.52M Buy
92,164
+6,788
+8% +$489K 7.39% 4
2015
Q1 		$6M Buy
85,376
+9,024
+12% +$612K 5.59% 4
2014
Q4 		$4.91M Buy
76,352
+8,409
+12% +$536K 5.14% 4
2014
Q3 		$4.32M Sell
67,943
-7,536
-10% -$467K 5.79% 4
2014
Q2 		$4.68M Buy
75,479
+2,433
+3% +$145K 6.22% 4
2014
Q1 		$4.26M Sell
73,046
-6,869
-9% -$388K 6.47% 5
2013
Q4 		$4.24M Sell
79,915
-2,945
-4% -$149K 7.6% 4
2013
Q3 		$3.96M Sell
82,860
-37,768
-31% -$1.79M 6.83% 6
2013
Q2 		$5.49M Buy
+120,628
New +$5.58M 5.72% 7

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Macroview Investment Management's PPH Position: Q4 2024 in Review

Macroview Investment Management sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2024, closing a stake of 144 shares — an estimated $13.7K sold.

Macroview Investment Management first reported a position in PPH in Q2 2013 and held it in 40 quarters. The position peaked at $6.52M in Q2 2015. 142 funds tracked by Wall St. Rank hold PPH as of Q4 2024.

  • Macroview Investment Management reported no remaining VanEck Pharmaceutical ETF position as of Q4 2024 after selling out during the quarter.
  • Macroview Investment Management sold 144 VanEck Pharmaceutical ETF shares in Q4 2024, an estimated $13.7K.
  • Macroview Investment Management first reported a position in VanEck Pharmaceutical ETF in Q2 2013 and held it in 40 quarters.
  • Macroview Investment Management's VanEck Pharmaceutical ETF position peaked at $6.52M in Q2 2015.
  • 142 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2024.

Based on Macroview Investment Management's 13F filing for Q4 2024, filed 31 Jan 2025.